NCT01421563

Brief Summary

The purpose of this study is compare the safety and pharmacokinetic characteristics of DP-R202 (Sarpogrelate HCl 300mg, qd) with those of Anplag (Sarpogrelate HCl 100mg, tid) after oral administration in healthy male volunteers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P50-P75 for phase_1 healthy

Timeline
Completed

Started Feb 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2011

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2011

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 27, 2011

Completed
27 days until next milestone

First Posted

Study publicly available on registry

August 23, 2011

Completed
Last Updated

August 23, 2011

Status Verified

August 1, 2011

Enrollment Period

Same day

First QC Date

July 27, 2011

Last Update Submit

August 22, 2011

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

  • Cmax, AUClast

    24h

Secondary Outcomes (1)

  • tmax, t1/2, AUC0-∞

    24h

Study Arms (2)

Anplag

ACTIVE COMPARATOR
Drug: Anplag

DP-R202

EXPERIMENTAL
Drug: Anplag

Interventions

AnplagDRUG

Sarpogrelate HCl 300mg once a day or 100mg three times a day

Also known as: DP-R202 : DP11002-2, Anplag : 0007
AnplagDP-R202

Eligibility Criteria

Age20 Years - 55 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • to 55 years of healthy volunteers

You may not qualify if:

  • Hypersensitivity Reaction about Sarpogrelate HCL or other antiplatelets

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Medical Center

Seoul, 135-710, South Korea

Location

Study Officials

  • JaeWook Ko, M.D., Ph.D.

    Samsung Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 27, 2011

First Posted

August 23, 2011

Study Start

February 1, 2011

Primary Completion

February 1, 2011

Study Completion

February 1, 2011

Last Updated

August 23, 2011

Record last verified: 2011-08

Locations

KR(1)